Metabolism and disposition of lesinurad, a uric acid reabsorption inhibitor, in humans
Sign Up to like & getrecommendations! Published in 2019 at "Xenobiotica"
DOI: 10.1080/00498254.2018.1504257
Abstract: Abstract The objectives of this study were to determine the absolute bioavailability of lesinurad and to characterized its disposition in humans. The oral bioavailability assessment was performed using a clinical design of simultaneous dosing of… read more here.
Keywords: disposition; lesinurad uric; metabolism disposition; disposition lesinurad ... See more keywords
Advances in Urate-Lowering Therapy: Time to Revisit High-Dose Febuxostat.
Sign Up to like & getrecommendations! Published in 2017 at "American journal of therapeutics"
DOI: 10.1097/mjt.0000000000000565
Abstract: Successful gout treatment depends almost entirely on lowering serum urate levels.1 Over the last decade, the Food and Drug Administration (FDA) approved 3 new urate-lowering medications: febuxostat, pegloticase, and lesinurad (joining the long-ago-approved drugs allopurinol… read more here.
Keywords: uric acid; febuxostat; trial; drug ... See more keywords